Acadia's Alzheimer's psychosis drug misses main goal of mid-stage study

Acadia Pharmaceuticals' experimental treatment for psychosis associated with Alzheimer's disease failed the primary endpoint in a mid-stage trial, showing it did not sufficiently reduce patient hallucinations and delusions. The setback materially weakens the program's development outlook and is likely to pressure Acadia shares.